Company / Profit Margin
Esperion Therapeutics, Inc. Profit Margin History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-5.6%
FY2025
5-year range
-343.0% / -5.6%
FY2021-FY2025
Trend
+63.8%
vs FY2024
Sector context
#68 of 146
Health Care
What the data says
At -5.6%, Esperion Therapeutics, Inc.'s profit margin ranks #68 of 146 in the Health Care sector. Profit Margin has increased for 4 consecutive years, from -343.0% in FY2021 to -5.6% in FY2025.
Based on SEC 10-K filings.
-5.6% in FY2025 with a 5-year CAGR of +57.5%.
Improved from -179.9% to -5.6% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- +304.0pp
- 5-Year Change
- +57.5pp
- 10-Year Change
- -
Sector benchmark
#68 of 146 in Health CareTop 47% of 146This company -5.6% Sector average -796.3%
▼
+99.3% above sector average
Key checks
Key Insights
- Esperion Therapeutics, Inc.'s profit margin has grown for 4 consecutive years.
- In FY2025, profit margin increased 63.8% year-over-year.
- Currently 790.6pp above the Health Care sector average.
- Lowest profit margin in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -1.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -15.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -5.6% | +63.8% |
| FY2024 | -15.6% | +91.3% |
| FY2023 | -179.9% | +41.9% |
| FY2022 | -309.6% | +9.8% |
| FY2021 | -343.0% | -443.7% |
| FY2020 | -63.1% | +3.7% |
| FY2019 | -65.5% | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026